Replies to post #249615 on Biotech Values

[marthambles]

PHAT - Had a discussion about this on Twitter. What I learned was the GERN market is pretty much all generic. So it might be tough for PHAT to get market share. Not sure Vonoprazan is sufficiently differentiated from PPI's.